Business Context and Reporting Period
Company: Altimmune, Inc.
Filing Type: Form 8-K (Current Report)
Date: September 14, 2022
Context: The filing discloses the announcement of results from a Phase 1b clinical study of the investigational drug pemvidutide (ALT-801) for the treatment of non-alcoholic fatty liver disease (NAFLD).
Key Financial Metrics
This Form 8-K is a disclosure of clinical trial results and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Results
The primary material event is the successful completion of a 12-week, randomized, double-blind, placebo-controlled Phase 1b study involving 94 subjects. Key outcomes include:
- Primary Endpoint: The trial met its primary endpoint of percent reduction in liver fat content in all pemvidutide treatment groups.
- Liver Fat Reduction: At the 1.8 mg dose, the mean relative reduction in liver fat content was 68.5%. Notably, 94.4% of subjects achieved a 30% reduction, 72.2% achieved a 50% reduction, and 55.6% achieved normalization of liver fat (defined as a liver fat fraction of 5% or less).
- Secondary Endpoint: The trial met its key secondary endpoint of percent weight loss. Mean weight losses were 4.9% (placebo-adjusted 4.7%) in subjects without diabetes and 4.4% (placebo-adjusted 3.9%) in subjects with diabetes at the 1.8 and 2.4 mg doses.
- Biomarkers: Mean serum alanine aminotransferase (ALT) levels declined in all subjects. Clinically meaningful reductions in systolic blood pressure were observed.
Outlook, Risks, and Safety Profile
Safety and Tolerability: Pemvidutide was reported to be generally well tolerated. Gastrointestinal events comprised the majority of adverse events (AEs) and were predominantly mild and transient. No serious or severe AEs were reported. Two subjects discontinued treatment due to gastrointestinal intolerability (one at 1.8 mg and one at 2.4 mg). No clinically significant ALT elevations were observed.
Management Commentary: The Company hosted a conference call to discuss these results and provided a slide presentation as Exhibit 99.2. The filing explicitly states that the Company undertakes no obligation to update, supplement, or amend the materials attached.
Risks: As with all clinical trials, future results may vary, and regulatory approval is not guaranteed. The filing notes that the trial did not employ dietary and exercise interventions standard for obesity trials.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) and slide presentation (Exhibit 99.2) for detailed statistical analysis and subgroup data.
- Confirm the specific dosing regimens and titration schedules used in the study to assess scalability for future Phase 2/3 trials.
- Review the Company's subsequent filings (e.g., 10-Q or 10-K) for updated cash runway and burn rate, as this 8-K does not contain financial data.
- Monitor for any regulatory feedback or updates on the timeline for initiating Phase 2 studies based on these Phase 1b results.